Yes, hydroxychloroquine kills malaria parasites and is one of the oldest tools still used to treat and prevent malaria. It works against all five species of Plasmodium that infect humans, though widespread drug resistance has limited where it remains effective. Outside of malaria, its role against other parasites is minimal.
How It Kills the Parasite
Malaria parasites survive inside red blood cells by digesting hemoglobin, the protein that carries oxygen in your blood. This digestion releases a byproduct called heme, which is toxic to living cells, including the parasite itself. To avoid being poisoned by its own meal, the parasite converts heme into a harmless crystallized form and stores it safely inside a compartment called the food vacuole.
Hydroxychloroquine is a weak base that slips easily through cell membranes. Once inside the parasite’s acidic food vacuole, it becomes chemically trapped. Because the drug carries two sites that can pick up hydrogen ions, it accumulates at far higher concentrations inside the vacuole than a simpler molecule would. This buildup raises the vacuole’s pH and, more importantly, shuts down the parasite’s ability to detoxify heme. Research published in the Journal of Experimental Medicine found that the drug reduces the parasite’s heme-detoxifying activity by 80 to 90 percent. Toxic heme then accumulates to lethal levels, destroying the parasite’s membranes from the inside out.
Which Malaria Species It Treats
The CDC lists hydroxychloroquine as a treatment option for all major Plasmodium species, with important geographic caveats:
- P. falciparum (the deadliest species): only treatable with hydroxychloroquine in a handful of regions that remain chloroquine-sensitive, specifically Central America west of the Panama Canal, Haiti, and the Dominican Republic. Everywhere else, resistance makes the drug unreliable.
- P. vivax and P. ovale: treatable in all malaria-endemic regions except Papua New Guinea and Indonesia, where chloroquine-resistant P. vivax emerged in 1989 and remains a major problem.
- P. malariae and P. knowlesi: treatable in all endemic regions. No confirmed resistance has been documented for these species.
The drug is also considered safe for treating malaria during pregnancy in regions where parasites remain sensitive.
How Quickly It Works
During an acute malaria infection, hydroxychloroquine begins clearing parasites from the bloodstream within the first couple of days. Fever typically breaks within 24 to 48 hours of starting treatment. Parasite levels in the blood drop significantly by 48 to 72 hours, and pain symptoms fade quickly alongside the fever. The full treatment course for uncomplicated malaria involves four doses spread over 48 hours: an initial loading dose followed by additional doses at 6, 24, and 48 hours.
For P. vivax and P. ovale infections, hydroxychloroquine only kills parasites circulating in the blood. These two species can hide dormant forms in the liver that reactivate weeks or months later. A second medication is needed to eliminate those dormant stages and prevent relapse.
Malaria Prevention
Hydroxychloroquine is also used as a weekly preventive medication for travelers heading to regions where malaria parasites remain sensitive to the drug. The standard adult dose is taken once per week, starting one to two weeks before entering the malaria zone and continuing for four weeks after leaving. Children receive a weight-based dose that does not exceed the adult amount. Because resistance has made the drug ineffective in most of sub-Saharan Africa and Southeast Asia, other preventive medications are recommended for those destinations.
The Drug Resistance Problem
Chloroquine-resistant P. falciparum first appeared independently in Southeast Asia, Oceania, and South America in the late 1950s and early 1960s. Since then, resistance has spread to nearly every region where falciparum malaria exists. Hydroxychloroquine and chloroquine share the same mechanism and the same resistance profile, so parasites resistant to one are resistant to both.
This is why the drug’s usefulness against the most dangerous malaria species is now limited to just a few pockets of the Americas and the Caribbean. For travelers and clinicians, knowing the resistance map is essential. Using hydroxychloroquine in a region with resistant parasites can mean the difference between clearing an infection and having treatment fail entirely.
Does It Work Against Other Parasites?
Hydroxychloroquine’s antiparasitic action is highly specific to Plasmodium. Its mechanism depends on disrupting heme detoxification inside red blood cells, a process unique to malaria parasites. There has been limited investigation into using the drug against other protozoa like Giardia, with a small number of older studies from the 1960s exploring this possibility, but it never became a standard treatment. For intestinal parasites, amoebic infections, and other protozoan diseases, different medications remain the established options.
Side Effects With Long-Term Use
For short-term malaria treatment or weekly prevention during travel, hydroxychloroquine is generally well tolerated. The side effects that draw the most concern arise with long-term use, which is common because the drug is widely prescribed for autoimmune conditions like lupus and rheumatoid arthritis.
The most serious long-term risk is retinal toxicity. Higher cumulative doses over years of use are associated with thinning of the outer layers of the retina, particularly in the central and surrounding areas responsible for detailed vision. This damage can be irreversible if not caught early. People taking the drug for extended periods are typically monitored with regular eye exams to detect changes before vision is affected. For someone using it only for a brief course of malaria treatment or a few months of travel prophylaxis, this risk is not a practical concern.